Thera-SAbDab

TANEZUMAB

>   Structural Summary
TherapeuticTanezumab
TargetNGFB
Heavy ChainQVQLQESGPGLVKPSETLSLTCTVSGFSLIGYDLNWIRQPPGKGLEWIGIIWGDGTTDYNSAVKSRVTISKDTSKNQFSLKLSSVTAADTAVYYCARGGYWYATSYYFDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASQSISNNLNWYQQKPGKAPKLLIYYTSRFHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQEHTLPYTFGQGTKLEIK
100% seqID Fv Structure4edw [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedRinat Neuroscience, Pfizer
Conditions Approvedna
Conditions ActiveBack pain, Cancer pain, Musculoskeletal pain, Pain
Conditions DiscontinuedDiabetic neuropathies, Postherpetic neuralgia
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]